How Have Orphan Drugs Changed the Specialty Landscape Over the Past Few Years?


 
Gilbert: I think orphan drugs have made significant changes to the specialty pharmacy landscape recently, specifically because some of these drugs are coming to disease states that have never had treatment before and also have extremely small patient population.
 
That requires us as specialty pharmacies to really be targeted and focused on those specific needs of those small patient populations, which are unique from other patient populations that we have dealt with in the past. 

Most Popular

Related Articles

Emapalumab (Gamifant) is the first treatment specifically approved for primary hemophagocytic lymphohistiocytosis, a rare and life-threatening immune disease.
In a session held at the National Association of Specialty Pharmacy Annual Meeting and Educational Conference, Kara E Cardinale, MPA, provided an update on regulatory actions in the health care space by the Centers for Medicare and Medicaid Services (CMS) and Department of Health and Human Services.
In a presentation held at the 2018 National Association of Specialty Pharmacy Annual Meeting and Educational Conference, Doug Long, MBA, provided insight into the growth of specialty, citing several areas to watch over the next few years.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$